Recruiting nowNot applicableObservational
What this study is about
The goal of this prospective observational study is to identify and validate blood based aging biomarkers in relation to cardiometabolic phenotypes of young and old, female and male subjects with or without obesity. The main question is to gain insights into the interaction of obesity related metabolic alteration and aging, and the relevance of loss of metabolic control in the development of age-related diseases in order to build a foundation for targeted drug- and lifestyle interventions in future studies.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersAccepted
ConditionObesity, Aging, Aging Problems, Metabolic Syndrome
Full registry criteria
Inclusion Criteria: Group 1 - Lean, young adults (n = 150) * Age 18 - 35 years * Body mass index (BMI) ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 12 months) Group 2 - Overweight, young adults (n = 150) * Age 18 - 35 years * BMI ≥ 28kg/m2 (≥ 12 months) Group 3 - Lean, older adults (n = 150) * Age ≥ 60 years * BMI ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 3 years) Group 4 - Overweight, older adults (n = 150) * Age ≥ 60 years * BMI ≥ 28 kg/m2 (≥ 3 years) * Subgroup A (n=75): with pre-existent cardiovascular disease defined as: history of myocardial infarction or evidence of coronary artery disease irrespective of revascularization status or history of ischemic or hemorrhagic stroke or presence of peripheral artery disease or heart failure with preserved ejection fraction (NYHA Class I-II). * Subgroup B (n=75): without pre-existent cardiovascular disease Group 5 - Nonagenerians Age ≥ 90 (n = 50) * Age ≥ 90 years * BMI ≥ 18.5 kg/m2 (≥ 3 years) Exclusion Criteria: Group 1 - Lean, young adults (n = 150) * Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\]) * Special diets (i.e. ketogenic diet and time-restricted eating) * Clinically significant metabolic or endocrine disorders * Claustrophobia * drug abuse, alcohol \> 15 drinks/week * Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions * Metal implants that prohibit 3T MRI * Pregnancy or breastfeeding Group 2 - Overweight, young adults (n = 150) * Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\]) * Special diets (i.e. ketogenic diet and time-restricted eating) * Active anti-obesity treatment (e.g. glucagon-like peptide 1 (GLP-1) analogues, polyagonists, naltrexone and bupropion) * Clinically significant metabolic or endocrine disorders * Claustrophobia * drug abuse, alcohol \> 15 drinks/week * Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions * Metal implants that prohibit 3T MRI * Pregnancy or breastfeeding Group 3 - Lean, older adults (n = 150) * Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\]) * Special diets (i.e. ketogenic diet and time-restricted eating) * Diabetes, overt hypo/hyperthyroidism * Claustrophobia * drug abuse, alcohol \> 15 drinks/week * Metal implants that prohibit 3T MRI * Known severe cardiovascular diseases (i.e. PAD IIa or higher, advanced heart failure = left ventricular ejection fraction (LVEF) \< 35% or NYHA Class III-IV) * No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years. * Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial. Group 4 - Overweight, older adults (n = 150) * Special diets (i.e. ketogenic diet and time-restricted eating) * Diabetes, overt hypo/hyperthyroidism * Active anti-obesity treatment (e.g. GLP-1 analogues, polyagonists, naltrexone and bupropion) * Claustrophobia * drug abuse, alcohol \> 15 drinks/week * Metal implants that prohibit 3T MRI * No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years. * Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial. Group 5 - "healthy" Nonagenerians Age ≥ 90 (n = 50) * Claustrophobia * Clinically significant cognitive impairment compromising study adherence * Metal implants that prohibit 3T MRI * Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.
Treatments and study arms
comprehensive metabolic phenotyping
Diagnostic Test
The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
